Invivyd Inc

NASDAQ:IVVDUnited States

Invivyd, Inc. is a commercial-stage company, which is engaged in delivering antibody-based therapies. The Company’s proprietary INVYMAB platform approach combines state-of-the-art viral surveillance and predictive modeling with advanced antibody engineering. INVYMAB is designed to facilitate the rapid, serial generation of new monoclonal antibodies (mAbs) to keep pace with evolving viral threats. The Company delivers antibody-based therapies that protect vulnerable people from the devastating consequences of circulating viral threats, such as SARS-CoV-2 (COVID-19). Its PEMGARDA is the Company’s first mAb in a planned series of innovative mAb candidates designed to keep pace with SARS-CoV-2 viral evolution. Its VYD2311 is optimized for neutralization potency against recent SARS-CoV-2 lineages such as BA.2.86 and JN.1. The Company also has additional anti-SARS-CoV-2 mAb candidates in discovery and pre-clinical characterization.

Contact Information

Headquarters

1601 Trapelo Road, Suite 178WALTHAM, MA, United States 02451

Phone

781-819-0080

Fax

302-655-5049

Executives

Independent Chairman of the Board

Marc Elia

Interim Chief Executive Officer, Chief Operating Officer, Chief Commercial Officer

Jeremy Gowler

Chief Financial Officer

William Duke

Chief Technology and Manufacturing Officer

Stacy Price

Chief Medical Officer

Pete Schmidt